“The right to life is the foundation of all human rights. The taking of life is irreversible, and goes against our fundamental belief in thedignity and worth of every human being. I call on all world leaders, legislators and justiceofficials to stop executions now. There is no place for the death penalty in the 21st century.” – Ban Ki-moon
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome.
INPUD (the International Network of People who Use Drugs) and ANPUD (the Asian Network of People who Use Drugs) urgently request a halt be called on the killing of people who use drugs in the Philippines. We implore Your Excellency President Duterte to reconsider the current approach of executing people who use drugs in favour of internationally accepted, evidence-based alternatives.
ANPUD embarked on this project, to begin to investigate and document the barriers to diagnosis, management and treatment of HCV amongst PWID. This investigation and documentation provides some of the necessary foundations for the next steps, in which ANPUD will develop a regional hepatitis C advocacy strategy.
WHO updated its hepatitis C treatment guidelines to provide recommendations for the use of these new medicines. The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred regimens based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014.
In this report, the International Drug Policy Consortium (IDPC) offers recommendations based on evidence and examples of good practice to inform a shift in policy responses to drug use in Asia away from criminalization and punishment, and towards public health and harm reduction. It describes effective approaches to the decriminalization of drug use. It also discusses approaches implemented in Asia that have proven ineffective, such as the detention of people who use drugs in compulsory centres as a form of ‘rehabilitation’.
The present Policy Brief was developed by the Asian Network of People who Use Drugs (ANPUD) to stimulate and support the meaningful participation of its constituents – Asian people who use drugs – in the UNGASS 2016 process. Following a short overview of the UNGASS process, the Brief highlights common issues across the region that have been prioritized by ANPUD with specific recommendations.
The challange of synthetic drugs in East and South East Asia and Oceania – Trends and patterns of Amphetamine-type stimulants and new psychoactive substances; Global SMART PROGRAMME MAY 2015
UNAIDS Reference Group on HIV and Human Rights as input to the study currently being conducted by the Office of the High Commissioner for Human Rights on the impact of the world drug problem on human rights. This study will be the primary contribution of the Human Rights Council to the UNGASS on Drugs.
More than 100 stakeholders from around the world met at UNAIDS headquarters to develop recommendations to help realize the 90–90–90 HIV treatment targets. The ambitious targets by 2020 are to ensure that 90% of all people living with HIV will know their HIV status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral suppression.